Headlines

Biologics driving M&A as Agilent snaps up specialist BIOVECTRA for $925 million

As advanced therapies drive increasing market consolidation, the US giant Agilent Technologies has acquired the Canadian contract development and manufacturing organization (CDMO) BIOVECTRA for $925 million.

Third Arc Bio raises $165M series A to develop biologics for cancer and immunology

The oversubscribed fundraising will enable Third Arc Bio to enter the clinic with multiple programs in 2025.

Alvotech and Stada debut uzpruvo, the first ustekinumab biosimilar in Europe

Alvotech and Stada launch Stelara biosimilar following European approval earlier this year and expiry of exclusivity rights on the original molecule.

Rona Therapeutics raises $35M in series A+ to advance metabolic siRNA therapeutics

The fundraising will support the development of the company’s technology platform for silencing RNA (siRNA), which has the potential to enable dosing patients every six months to treat a wide range of conditions.

Pluri’s CDMO arm takes on ALS and diabetes in cell therapy deal

The contract development and manufacturing organization (CDMO) arm of the Israeli company Pluri will deploy automated and 3D cell expansion technology to produce cell therapies developed by compatriot firm Kadimastem.

Ionis announces positive early results for Angelman syndrome therapy

Ionis Pharmaceuticals antisense therapy for Angelman syndrome achieved good early safety and efficacy results and the company now plans to advance the therapy to phase 3.

CordenPharma invests €900M in expanding peptide platform to meet GLP-1 drug demand

CordenPharma, a US-based contract development and manufacturing organization (CDMO), will be making a €900 million investment over the next three years into expanding its peptide technology platform at its US and Europe sites.

Top 5 CDMOs driving advanced therapies to market amid rising demand and challenges

Contract development and manufacturing organizations (CDMOs) perform vital services for the biopharmaceutical industry – a role that is growing as cell and gene therapies gain momentum. Here are five of the top CDMOs bringing advanced therapies toward...

Global Industry News

Trends

Spotlight

Laura Child on passion, career challenges, and advice for young women in life sciences

Women in Science - Jasmina Jankicevic, her life in science

Women in Science - Jasmina Jankicevic from founding organizations for the prevention of HIV to CMO at Innovaderm Research

CytoDyn secures $12M as dispute with CRO reaches settlement: Positive impact on antibody drug trials

SciRhom raises €63M in series A to develop antibodies against autoimmune diseases

Featured Suppliers

All

Headlines

Biologics driving M&A as Agilent snaps up specialist BIOVECTRA for $925 million

Third Arc Bio raises $165M series A to develop biologics for cancer and immunology

Alvotech and Stada debut uzpruvo, the first ustekinumab biosimilar in Europe

Rona Therapeutics raises $35M in series A+ to advance metabolic siRNA therapeutics

Pluri’s CDMO arm takes on ALS and diabetes in cell therapy deal

Ionis announces positive early results for Angelman syndrome therapy

CordenPharma invests €900M in expanding peptide platform to meet GLP-1 drug demand

Top 5 CDMOs driving advanced therapies to market amid rising demand and challenges

Roche’s oral GLP-1 receptor agonist shows promising early weight loss results in phase 1

FDA delays approval of Novo Nordisk’s weekly insulin until requests are met

Lexeo’s gene therapy shows promising phase 1/2 results for Friedreich's ataxia cardiomyopathy

Rentschler opens advanced therapy production line as CDMO demand surges

HilleVax halts development of world’s most advanced norovirus vaccine after phase 2 failure

Global Industry News

IQVIA’s One Home for Sites: Reducing tech overload in clinical research

Ask the experts: Should pharmacists take on more responsibility or is it a stretch too far?

Suzanne LeBlang - passionate about patient care and the Focused Ultrasound Foundation

Trends

Funding boost to scale production for human vaccines and expand R&D labs

Ensuring pharma data integrity: COPA-DATA’s automation solution tackles ALCOA challenges

Global biosimilar market estimated to reach a size of $43.8 billion by the end of 2024

FDA approves Samsung Bioepis’ Epsyqli biosimilar for PNH and aHUS treatment

Boehringer Ingelheim and GoodRx undercut Humira by massive 92% with biosimilar

Women in science: Trailblazing neurologist Antonella Favit-VanPelt's sound advice for success

Spotlight

Follow us

Most popular News

Featured Suppliers

BioPharma-Reporter

Resources